Neuroblastoma | CHOP Research Institute


Published on
Nov 10, 2023
This week’s research news features awards for furthering patient-centered outcomes research careers and for recognizing the importance of mentorship.
Published on
Apr 14, 2023
Learn about a technique to analyze large datasets, preclinical results that show safety and efficacy of a drug that could help children with high-risk neuroblastoma, and a milestone in the CORSICA project that seeks to cure rare sinonasal cancers.

Dr. Wolpaw’s laboratory seeks to develop an understanding of how tumor heterogeneity and epigenetics impact inflammatory signaling and immunotherapy responses in pediatric solid tumors with a goal of developing more efficacious, less toxic therapies to treat these devastating diseases.

Published on
Sep 19, 2022
CHOP physician-scientists discuss their CAR T-cell therapy research for childhood cancers in Where Discovery Leads.

Dr. Evageliou is an attending physician in the Division of Oncology. His research interest is in renal tumors, neuroblastoma, and solid tumors. He is a member of the Renal Tumors Committee of the Children's Oncology Group, where he helps create clinical trials for Wilms tumors.

evageliou [at]
Published on
Jun 29, 2022
CHOP scientists are part of a Cancer Grand Challenges team receiving $25 million to tackle solid tumors.

Dr. Pogoriler's research focuses on pediatric lung disease and neoplasia. These interests come together in her work on congenital cystic lung lesions and their potential premalignant diagnosis. She collaborates with both clinicians and basic scientists on pediatric cancer research.

pogorilerj [at]
Published on
Feb 4, 2022
Learn about novel findings neuroblastoma, MIS-C, and more in this week's roundup of research news.
Published on
Jan 3, 2022
Congratulations to Garrett Brodeur, MD, recipient of the American Society of Pediatric Hematology/Oncology Distinguished Career Award.
Published on
Dec 30, 2021
Here’s our list of the 2021 Cornerstone stories our social media followers engaged with the most.